房颤多重用药患者中利伐沙班、阿哌沙班与华法林的效果比较
本研究利用美国联邦医疗保险行政数据,纳入2015至2017年新诊断房颤并在90天内启动口服抗凝药的患者,按合并用药数量分为低、中、高多重用药组,采用三向倾向性评分匹配比较阿哌沙班、利伐沙班与华法林的有效性与安全性。结果显示,在高多重用药组中,阿哌沙班相比华法林与利伐沙班可能增加缺血性卒中与死亡风险,但差异仅为临界显著性。
要点
- 高多重用药(>8种其他药物)房颤患者中,阿哌沙班相比华法林缺血性卒中风险更高(aHR 2.34)。
- 高多重用药组中,阿哌沙班相比利伐沙班全因死亡风险更高(aHR 2.03)。
- 低多重用药组中,阿哌沙班相比华法林出血风险更低(aHR 0.54)。
核心结论
- 在合并用药超过8种的房颤患者中,阿哌沙班相比华法林和利伐沙班可能伴随更高的卒中与死亡风险,但差异仅为临界显著性。
研究设计与样本
- 基于美国联邦医疗保险行政数据的回顾性队列研究,纳入2015至2017年新诊断房颤并在90天内启动口服抗凝药的患者。
- 按合并用药数量分为低(≤3种)、中(4-8种)、高(≥9种)多重用药组,并在各组内进行三向倾向性评分匹配。
主要发现
- 匹配队列包括阿哌沙班6985例、利伐沙班3838例、华法林6639例。
- 低与中多重用药组中,三种药物缺血性卒中风险无差异。
- 高多重用药组中,阿哌沙班相比华法林缺血性卒中风险更高(aHR 2.34,95%CI 1.01-5.42,P=0.05),与利伐沙班相似(aHR 1.38,95%CI 0.67-2.84,P=0.4)。
- 高多重用药组中,阿哌沙班相比利伐沙班全因死亡风险更高(aHR 2.03,95%CI 1.01-4.08,P=0.05)。
- 低多重用药组中,阿哌沙班相比华法林出血风险更低(aHR 0.54,95%CI 0.32-0.90,P=0.02);中与高多重用药组中三药出血风险无差异。
临床怎么用
- 对于合并用药超过8种的房颤患者,选择阿哌沙班时需权衡潜在的卒中与死亡风险,考虑华法林或利伐沙班作为替代。
- 低多重用药患者中阿哌沙班的较低出血风险可作为用药选择参考。
局限性
- 本研究为回顾性行政数据分析,可能存在残余混杂。
- 高多重用药组中观察到的差异仅为临界显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation and high polypharmacy are unknown. METHODS: We used Medicare administrative data to evaluate patients with new atrial fibrillation diagnosis from 2015 to 2017, who initiated an oral anticoagulant within 90 days of diagnosis. Patients taking ≤3, 4 to 8, or ≥9 other prescription medications were categorized as having low, moderate, or high polypharmacy, respectively. Within polypharmacy categories, patients receiving apixaban 5 mg twice daily, rivaroxaban 20 mg once daily, or warfarin were matched using a 3-way propensity score matching. Study outcomes included ischemic stroke, bleeding, and all-cause mortality. RESULTS: The study cohort included 6985 patients using apixaban, 3838 using rivaroxaban, and 6639 using warfarin. In the propensity-matched cohorts there was no difference in risk of ischemic stroke between the 3 drugs in patients with low and moderate polypharmacy. However, among patients with high polypharmacy, the risk of ischemic stroke was higher with apixaban compared with warfarin (adjusted hazard ratio 2.34 [95% CI, 1.01-5.42]; P=0.05) and similar to rivaroxaban (adjusted hazard ratio, 1.38 [95% CI, 0.67-2.84]; P=0.4). There was no difference in risk of death between the 3 drugs in patients with low and moderate polypharmacy, but apixaban was associated with a higher risk of death compared with rivaroxaban (adjusted hazard ratio, 2.03 [95% CI, 1.01-4.08]; P=0.05) in the high polypharmacy group. Apixaban had lower bleeding risk compared with warfarin in the low polypharmacy group (adjusted hazard ratio, 0.54 [95% CI, 0.32-0.90]; P=0.02), but there was no difference in bleeding between the 3 drugs in the moderate and high polypharmacy groups. CONCLUSIONS: Our study suggests that among patients with significant polypharmacy (>8 drugs), there may be a higher stroke and mortality risk with apixaban compared with warfarin and rivaroxaban. However, differences were of borderline significance.
引用
- Mentias A, Heller E, Vaughan Sarrazin M, et al. Comparative Effectiveness of Rivaroxaban, Apixaban, and Warfarin in Atrial Fibrillation Patients With Polypharmacy. Stroke. 2020. PMID: 32517580. doi:10.1161/STROKEAHA.120.029541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。